Navigation Links
Hospira Shares Results From Two Open-label Extension Studies for Biosimilar Infliximab in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis
Date:10/31/2013

LAKE FOREST, Ill., Oct. 31, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, this week shared the results of two open-label extension studies of CT-P13 (infliximab), one in patients with rheumatoid arthritis, the other in patients with ankylosing spondylitis, which were presented at the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in San Diego. Hospira's CT-P13, branded as Inflectra, was approved by the European Medicines Agency (EMA) in September 2013 as a biosimilar to reference product, Remicade® (infliximab). Inflectra is not currently approved for use in the United States.

The objective of these open-label extension studies was to confirm long-term efficacy and safety of Inflectra in patients who had completed the original 54-week European Union (EU) clinical studies and to investigate switching from the reference Remicade product to Inflectra.

In one study, 302 of 455 patients with rheumatoid arthritis who completed the Phase III PLANETRA study entered into the open-label extension phase. Of these, 158 were continuously treated with Inflectra (maintenance group) and 144 were switched from Remicade to Inflectra (switch group) for one additional year.  The maintenance group and the switch group at weeks 78 and 102 were similar as measured by American College of Rheumatology (ACR) ACR20/50/70, DAS28-CRP, DAS28-ESR, EULAR-CRP, and EULAR-ESR response rates. Overall incidence of treatment-emergent adverse events (TEAE) was similar in both groups.

In the other study, 174 of 210 patients with ankylosing spondylitis who com
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Hospira Unveils New Quality Laboratory and Investments at Rocky Mount, N.C., Plant
2. Hospira Launches Q Core Sapphire Infusion System in the United States
3. Gastroenterologists Unlikely To Use Celltrion/Hospiras Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease
4. Hospira to Present at the Morgan Stanley Global Healthcare Conference
5. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
6. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
7. Hospira dévoile sa stratégie appareil mondiale
8. Hospira enthüllt weltweite Gerätestrategie
9. Hospira revela estrategia global para sus dispositivos
10. Hospira revela estratégia global para dispositivos
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Major advances in radiation therapy and radiosurgery ... in a three-day Oncology Summit taking place in ...  Renowned national and international cancer experts from seven countries ... knowledge on modern technologies making treatment for cancer ... The Summit will address a wide spectrum ...
(Date:7/10/2014)... 10, 2014  The U.S. Department of Health and ... University Hospitals (UH) Case Medical Center Seidman Cancer Center ... aimed at improving care for patients with complex cancer. ... will test a unique model developed at UH to ... significant comorbidities, or demonstrated need for high health care ...
(Date:7/10/2014)... 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... analog IC solutions, today announced that it will host ... at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) ... 2014 third quarter ended June 30, 2014. ... before 6:50 a.m. Pacific time on July 24, 2014.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... Inc. (Nasdaq: VNDA ), announced today that ... for tasimelteon, an oral dual melatonin receptor agonist in ... in blind individuals with no light perception. This follows ... for Orphan Medicinal Products (COMP) of the European Medicines ...
... LAKE FOREST, Ill., March 7, 2011 The board of ... global specialty pharmaceutical and medication delivery company, today announced the ... chief executive officer (CEO) and a member of the board, ... Inc., succeeds the company,s founding CEO, Christopher B. Begley, who ...
Cached Medicine Technology:Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 2Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 4Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role 2Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role 3Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role 4
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... liver damage allegations continue to move forward in ... Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP ... 2014, U.S. District Judge Lawrence F. Stengel has ... Among other things, Judge Stengel found that the ...
(Date:7/12/2014)... Burn injuries increase in the summer as people gather around ... those most vulnerable to these seasonal fire hazards: children. ... burned by putting their hands on the side of cooking ... at Loyola University Medical Center in Maywood, Ill., said in ... you play with fire, you get burned, is true -- ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of ... the use of his left side. Eating became a difficult task ... people like them enjoy eating again,” said an inventor, from Fayetteville, ... CAROL HALL PLATE (P C H PLATE). , The PATRICIA CAROL ... to eat for individuals who suffer from stroke, experience tremors or ...
(Date:7/12/2014)... 12, 2014 With prom shopping reaching ... and retailer, is ready to showcase its new and ... collection of evening dresses in its online shop. Additionally, ... off) for these elegant gowns. According to the company’s ... on July 26, 2014. , He says, “Now, ...
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... medical bodies in India have criticized the recent ... curriculum. , ,Mr.Vinay Agarwal, Secretary of Indian medical ... said: "The idea of adding ayurveda, unani and homoeopathy ... going to help anybody,", ,He added: "The move ...
... can affect younger men with clogged arteries leading to a ... the current issue of Psychosomatic Medicine. However, women in the ... said the study., ,The researchers from University of Helsinki ... the carotid arteries, which supply blood to the head, in ...
... been undergoing a revolution with increasing importance being given ... amount of resources allocated to research in specific genetic ... motivation to scientists working in the field of genetics ... those acquired new. One such breakthrough has been the ...
... that will help them to study the effects of lower ... hypertension and heart failure., ,Researchers at Wake Forest University ... by changing a single gene that is involved in hypertension. ... as well as explore how estrogen depletion affects several body ...
... a judgement to popularise smoking but a simple stating of facts., ... of Health and the Centre for Disease Control, // smokers are ... of concern for anti-smoking lobbies and doctors. As smoking can promote ... people who smoke are less likely to visit the dentist, even ...
... virus-induced diseases like bird flu and Japanese encephalitis, a ... virology. The NIV and the Institute of // Biotechnology ... the degree jointly., ,"There is a shortage of ... course is intended to provide qualified virologists to various ...
Cached Medicine News:Health News:Launch Of India’s First Virology Course At Pun 2
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
Medicine Products: